Research progress on the mechanism of drug resistance of Mycobacterium tuberculosis to ethionamide/pthionamide and ethionamide boosters

doi:10.3969/j.issn.1000-6621.2020.02.017

Abstract

Abstract:

Ethionamide (ETH)/prothionamide (PTH) are analogues of isoniazid (INH). They are usually used as second-line anti-tuberculosis drugs on treatment of multidrug resistant tuberculosis(MDR-TB). The clinical usage of ETH/PTH is affected by their cross resistance with INH, weak bactericidal effect and adverse reactions of digestive system they may induce. In recent years, researches of ETH boosters based on molecular mechanism of ETH/PTH have also made significant progress. In this review, the mechanism of ETH/PTH resistance, the mechanism of INH cross resistance and studies of ETH boosters were summarized.

Key words: Mycobacterium tuberculosis, Isoniazid, Ethionamide, Prothionamide, Tuberculosis,multidrug-resistant, Molecular mechanisms of pharmacological action, Review literature (as topic)

SONG Yan-hua,GAO Meng-qiu,LI Qi. Research progress on the mechanism of drug resistance of Mycobacterium tuberculosis to ethionamide/pthionamide and ethionamide boosters[J]. Chinese Journal of Antituberculosis, 2020, 42(2): 173-177. doi: 10.3969/j.issn.1000-6621.2020.02.017

References 38

[1]	World Health Organization . Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
[2]	World Health Organization . WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva:World Health Organization, 2019.
[3]	Schon T, Jureen P, Chryssanthou E , et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis, 2011,15(4):502-509.
[4]	Wang F, Langley R, Gulten G , et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med, 2007,204(1):73-78.
[5]	World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization, 2016.
[6]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
[7]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073.
[8]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
[9]	李静, 张阳奕, 桂晓虹 , 等. 上海市耐多药结核病患者二线药物耐药情况及危险因素分析. 中华流行病学杂志, 2012,33(8):795-798.
[10]	车洋, 杨天池, 平国华 , 等. 116例耐多药肺结核患者二线抗结核药物耐药情况分析. 疾病监测, 2016,31(9):766-770.
[11]	刘银萍, 王杰, 张俊仙 , 等. 对异烟肼与丙硫异烟胺耐药的结核分枝杆菌临床分离株检测及相关基因突变的研究. 中国防痨杂志, 2016,38(9):718-721.
[12]	陈惠芬, 黄秋生, 高爱霞 , 等. 耐多药结核分枝杆菌对二线抗结核药物敏感性观察. 南京医科大学学报(自然科学版), 2014,34(1):69-71.
[13]	李心德 . 174株耐多药结核分枝杆菌对二线抗结核药耐药情况分析. 国际检验医学杂志, 2014,25(13):1732-1733.
[14]	宋艳华, 王桂荣, 霍凤敏 , 等. 耐多药和广泛耐药MTB inhA基因突变与对丙硫异烟胺耐药的相关性分析. 中国防痨杂志, 2018,40(8):821-824.
[15]	Boonaiam S, Chaiprasert A, Prammananan T , et al. Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. Clin Microbiol Infect, 2010,16(4):396-399.
[16]	Morlock G, Metchock B, Sikes D , et al. ethA, inhA, and katG Loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother, 2003,47(12):3799-3805.
[17]	Rueda J, Realpe T, Mejia GI , et al. Genotypic analysis of genes associated with independent resistance and cross-resis-tance to isoniazid and ethionamide in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother, 2015,59(12):7805-7810.
[18]	Vilchèze C, Jacobs WR Jr . Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr, 2014, 2(4):MGM 2-0014-2013.
[19]	Vale N, Gomes P, Santos HA . Metabolism of the antituberculosis drug ethionamide. Curr Drug Metab, 2013,14(1):151-158.
[20]	Hok TT . A comparative study of the susceptibility to ethionamide, thiosemicarbazone, and isoniazid of tubercle bacilli from patients never treated with ethionamide or thiosemicarbazone. Am Rev Respir Dis, 1964,90:468-469.
[21]	Banerjee A, Dubnau E, Quemard A , et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science, 1994,263(5144):227-230.
[22]	Brossier F, Veziris N, Truffot-Pernot C , et al. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol, 2006,44(10):3659-3664.
[23]	Vilcheze C, Wang F, Arai M , et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med, 2006,12(9):1027-1029.
[24]	Zhang Y, Yew WW . Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis, 2015,19(11):1276-1289.
[25]	Leung ET, Ho PL, Yuen KY , et al. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA. Antimicrob Agents Chemother, 2006,50(3):1075-1078.
[26]	Tan Y, Su B, Zheng H , et al. Molecular characterization of prothionamide-resistant Mycobacterium tuberculosis isolates in Southern China. Front Microbiol, 2017,8:2358.
[27]	Brossier F, Cambau E, Tessier E , et al. The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis. Tuberculosis (Edinb), 2016,101:144-145.
[28]	Schaaf HS, Victor TC, Venter A , et al. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis, 2009,13(11):1355-1359.
[29]	Caroline L, Maria G, Aina S , et al. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. Antimicrobl Agents Chemother, 2005,49(10):4068.
[30]	贾莅莉, 高飞, 张硕 . 异烟肼高度耐药与丙硫异烟胺耐药关系. 内蒙古医学杂志, 2015,47(12):135.
[31]	DeBarber AE, Mdluli K, Bosman M , et al. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci U S A, 2000,97(17):9677-9682.
[32]	Brossier F, Veziris N, Truffot-Pernot C , et al. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2011,55(1):355-360.
[33]	Baulard AR, Betts JC, Engohang-Ndong J , et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem, 2000,275(36):28326-28331.
[34]	Flipo M, Desroses M, Lecat-Guillet N , et al. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. J Med Chem, 2012,55(1):68-83.
[35]	Rubin EJ . Reviving a drug for tuberculosis? N Engl J Med, 2017,376(23):2292-2294.
[36]	Blondiaux N, Moune M, Desroses M , et al. Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. Science, 2017,355(6330):1206-1211.
[37]	Wohlkönig A, Remaut H, Moune M , et al. Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2. Biochem Biophys Res Commun, 2017,487(2):403-408.
[38]	Inturi B, Pujar GV, Purohit MN . Recent advances and structural features of enoyl-ACP reductase inhibitors of Mycobacterium tuberculosis. Arch Pharm (Weinheim), 2016,349(11):817-826.